CD3-specific antibodies: a portal to the treatment of autoimmunity
Top Cited Papers
- 20 July 2007
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 7 (8) , 622-632
- https://doi.org/10.1038/nri2134
Abstract
Targeted immunotherapies hold great promise for the treatment and cure of autoimmune diseases. The efficacy of CD3-specific monoclonal antibody therapy in mice and humans stems from its ability to re-establish immune homeostasis in treated individuals. This occurs through modulation of the T-cell receptor (TCR)-CD3 complex (also termed antigenic modulation) and/or induction of apoptosis of activated autoreactive T cells, which leaves behind 'space' for homeostatic reconstitution that favours selective induction, survival and expansion of adaptive regulatory T cells, which establishes long-term tolerance. This Review summarizes the pre-clinical and clinical studies of CD3-specific monoclonal antibody therapy and highlights future opportunities to enhance the efficacy of this potent immunotherapeutic.Keywords
This publication has 102 references indexed in Scilit:
- Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatmentProceedings of the National Academy of Sciences, 2007
- Biochemical, molecular characterization, and glycoproteomic analyses of α1‐proteinase inhibitor products used for replacement therapy*Transfusion, 2006
- The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantationTransplant International, 2006
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsJournal of Clinical Investigation, 2006
- Dendritic cells: emerging pharmacological targets of immunosuppressive drugsNature Reviews Immunology, 2004
- Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.Journal of Clinical Investigation, 1997
- Hypothermia and hypoglycemia induced by anti‐CD3 monoclonal antibody in mice: Role of tumor necrosis factorEuropean Journal of Immunology, 1990
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αNew England Journal of Medicine, 1989